CNS Pharmaceuticals’ (CNSP) Hold Rating Reaffirmed at Maxim Group

Posted by ABMN Staff on Mar 27th, 2025

CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report)‘s stock had its “hold” rating reissued by analysts at Maxim Group in a research note issued to investors on Tuesday,Benzinga reports.

Separately, Alliance Global Partners upgraded shares of CNS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 24th.

Read Our Latest Stock Analysis on CNSP

CNS Pharmaceuticals Stock Performance

Shares of NASDAQ:CNSP opened at $1.41 on Tuesday. The company’s fifty day moving average is $4.02 and its two-hundred day moving average is $5.40. CNS Pharmaceuticals has a 1-year low of $1.28 and a 1-year high of $975.00. The stock has a market capitalization of $1.62 million, a price-to-earnings ratio of -0.02 and a beta of 2.65.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CNSP. Jane Street Group LLC lifted its stake in CNS Pharmaceuticals by 1,712.3% in the fourth quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock valued at $51,000 after buying an additional 396,577 shares during the last quarter. Citadel Advisors LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter valued at about $39,000. XTX Topco Ltd bought a new position in CNS Pharmaceuticals in the 4th quarter worth about $36,000. Connective Capital Management LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $34,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of CNS Pharmaceuticals during the fourth quarter valued at approximately $30,000. 14.02% of the stock is currently owned by institutional investors.

CNS Pharmaceuticals Company Profile

(Get Free Report)

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.